Search - tctmd.com

Displaying 1 - 20 of 1644

Sort: Relevancy | Date

Presentation TCT 2016

No-Contrast PCI: A Strategy Based on Intravascular Imaging and Physiology to Avoid Contrast-Induced Nephropathy

Presenter: Adrian P. Banning, Ryan D. Madder, Ziad A. Ali

November 01, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Think Twice: BRS First

Presenter: George D. Dangas, Fabio Felice Tarantino, Francesco Saia

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Case Presentation: Complex PCI in STEMI and Cardiogenic Shock

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Vladimir Ganyukov

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: ILUMIEN III: OPTIMIZE PCI and COLOR

Presenter: Giulio Guagliumi, Ik-Kyung Jang, Ron Waksman

November 01, 2016

Presentation TCT 2016

Risks of Antegrade CTO PCI: Lessons From Registry Data and Personal Experience

Presenter: Christopher E. Buller, Masahisa Yamane, Kambis Mashayekhi

November 01, 2016

Presentation TCT 2016

Stroke Interventions: Parallels to Primary PCI for Acute MI and the Potential Role of the Cardiologist

Presenter: D. Christopher Metzger, Bernhard Reimers

November 01, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

PASCAR: Global Hearts Sub-Saharan Africa PCI Capacity Survey Results

Presenter: Jack C. Lewin, Hugh J. Linnehan, Habib Gamra

November 01, 2016

Presentation TCT 2016

Risks of Retrograde CTO PCI: Lessons From Registry Data and Personal Experience

Presenter: Christopher E. Buller, Masahisa Yamane, Emmanouil S. Brilakis

November 01, 2016

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) from: EXCEL and NOBLE

Presenter: Yves R. Louvard, John D. Puskas, Davide Capodanno

November 01, 2016

Advertisement

No-Contrast PCI: A Strategy Based on Intravascular Imaging and Physiology to Avoid Contrast-Induced Nephropathy

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Case Conclusion: How Did We Treat Our Patient?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Think Twice: BRS First

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Choose a Drug-Eluting Stent: Heres Why

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Case Presentation: Complex PCI in STEMI and Cardiogenic Shock

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Highlights (and my Interpretations) From: ILUMIEN III: OPTIMIZE PCI and COLOR

Risks of Antegrade CTO PCI: Lessons From Registry Data and Personal Experience

Stroke Interventions: Parallels to Primary PCI for Acute MI and the Potential Role of the Cardiologist

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

PASCAR: Global Hearts Sub-Saharan Africa PCI Capacity Survey Results

Risks of Retrograde CTO PCI: Lessons From Registry Data and Personal Experience

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Highlights (and my Interpretations) from: EXCEL and NOBLE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content